Imbruvica — CareFirst (Caremark)
Chronic graft-versus-host disease (cGVHD)
Initial criteria
- Member has failed one or more lines of therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on Imbruvica
Approval duration
12 months